New Drug Improves Outcome in Treatment Resistant Kidney Cancer

the ONA take:

A new drug is proven more effective than standard therapies for advanced kidney cancer in patients with demonstrated drug resistance.

A study trial, led by researchers from the Dana-Farber Cancer Institute, compared the effectiveness of a new drug, cabozantinib, with the accepted second-line treatment, everolimus (Affinitor).

The trial enrolled 658 patients with clear cell renal carcinoma; all participants had advanced or metastatic renal cell carcinoma and their disease had worsened following first-line therapy.

Initial therapy for these patients had targeted the vascular endothelial growth factor receptor (VEGFR). Cabozantinib proved to be more effective than everolimus in slowing the growth of cancer in these patients and there were early indications that it may have improved their overall survival as well (progression-free survival was a median of 7.4 months vs 3.8 for those using everolimus).

Toni K. Choueiri, MD, clinical director of the Genitourinary Cancer Treatment Center at Dana-Farber Cancer Institute, and first author of the report, feels that cabozantinib may also have potential as a first-line treatment for kidney cancer.

Cabozantinib has received breakthrough therapy designation from the Food and Drug Administration. Report data were published online in the New England Journal of Medicine.

New Drug Improves Outcome in Treatment Resistant Kidney Cancer
A new drug is proven more effective than standard therapies for advanced kidney cancer in patients with demonstrated drug resistance.
A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs